Lantern Pharma (LTRN) Assets (2019 - 2026)

Lantern Pharma (LTRN) has reported Assets for 8 consecutive years, with $8.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets fell 50.62% year-over-year to $8.6 million; the trailing twelve-month figure through Jun 2026 stood at $8.6 million (down 50.62% YoY), and the FY2025 full-year result was $11.0 million, down 56.84% from the prior year.
• Assets grew to $8.6 million in Q2 2026 per LTRN's latest filing, from $7.2 million in the prior quarter.
• Across five years, Assets topped out at $68.4 million in Q1 2022 and bottomed at $7.2 million in Q1 2026.
• Historically, Assets has averaged $36.9 million across 5 years, with a median of $37.7 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Assets decreased 17.09% in 2022, then tumbled 65.76% in 2026.
• Over 5 years, Assets stood at $58.8 million in 2022, then retreated by 25.82% to $43.6 million in 2023, then sank by 41.41% to $25.6 million in 2024, then tumbled by 56.84% to $11.0 million in 2025, then retreated by 22.05% to $8.6 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $8.6 million, $7.2 million, and $11.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.